Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 23, Number 1—January 2017

CME ACTIVITY - Research

Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010

Xizhong Cui1, Leisha D. Nolen1, Junfeng Sun, Malcolm Booth, Lindsay Donaldson, Conrad P. Quinn, Anne E. Boyer, Katherine A. Hendricks, Sean Shadomy, Pieter Bothma, Owen Judd, Paul McConnell, William A. Bower, and Peter Q. EichackerComments to Author 
Author affiliations: National Institutes of Health, Bethesda, Maryland, USA (X. Cui, J. Sun, P.Q. Eichacker); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (L.D. Nolen, C.P. Quinn, A.E. Boyer, K. Hendricks, S. Shadomy, W.A. Bower); Glasgow Royal Infirmary, Glasgow, UK (M. Booth, L. Donaldson); James Paget University Hospital, Norfolk, UK (P. Bothma); Royal Derby Hospital, Derby, UK (O. Judd); Crosshouse Hospital, Kilmarnock, UK (P. McConnell)

Main Article

Table 3

Initial physical findings of recipients and nonrecipients of AIG-IV, Scotland, UK, 2009–2010*

Physical finding AIG-IV nonrecipient AIG-IV recipient p value
Vital signs [reference value]†
Temperature, °C, mean ± SE [36.1–37.2°C] 37.3 ± 0.3, n = 28 36.3 ± 0.4, n = 15 0.05
Systolic BP, mmHg, mean ± SE [90–140 mm Hg] 113.6 ± 3.8, n = 28 117.2 ± 5.0, n = 15 0.57
Diastolic BP, mmHg, mean ± SE [60–90 mm Hg] 65.9 ± 3.0, n = 28 68.6 ± 4.3, n = 15 0.59
Mean BP, mmHg, median (IQR) [70–100 mm Hg] 83.5 (74.3–90.7), n = 28 88.0 (67.7–93.3), n = 15 0.57
Heart rate, beats/min, mean ± SE [60–100 beats/min] 104.0 ± 4.7, n = 28 102.4 ± 5.3, n = 15 0.83
Respiratory rate, breaths/min, mean ± SE [12–20 breaths/min] 18.8 ± 1.4, n = 28 19.9 ± 1.7, n = 13 0.64
Glasgow coma score, median (IQR) [15]
 15 (15–15), n = 28
 15 (15–15), n = 15
 0.56
Skin and limbs
Skin lesion 85.2 (23/27) 73.3 (11/15) 0.43
Ulcer 35.3 (6/17) 10 (1/10) 0.20
Exude 27.8 (5/18) 18.2 (2/11) 0.68
Limb mottling 26.7 (4/15) 60 (6/10) 0.12
Eschar 17.7 (3/17) 18.2 (2/11) 1.00
Local pain 100 (19/19) 85.7 (12/14) 0.17
Localized edema 95.8 (23/24) 93.3 (14/15) 1.00
Local erythema 87.0 (20/23) 92.3 (12/13) 1.00
Limb pain 89.5 (17/19) 46.7 (7/15) 0.01
Limb edema
 84 (21/25)
 46.7 (7/15)
 0.03
Findings other than skin and limb
Fever 60.9 (14/23) 66.7 (8/12) 1.00
Diaphoresis 63.6 (7/11) 40 (4/10) 0.39
Lethargy 64.3 (9/14) 41.7 (5/12) 0.25
Nausea 29.4 (5/17) 30 (3/10) 1.00
Abdomen pain 6.7 (1/15) 20 (2/10) 0.54
Confusion 35.3 (6/17) 0 (0/13) 0.02

*Values are % patients (no. patients with the finding/no. patients for whom data were available) except as indicated. n values indicate no. patients for whom data were available. Bold indicates statistical difference between AIG-IV recipients and nonrecipients. AIG-IV, anthrax immune globulin intravenous; BP. blood pressure; IQR, interquartile range.

Main Article

1These authors contributed equally to this article.

Page created: December 14, 2016
Page updated: December 14, 2016
Page reviewed: December 14, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external